钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病并发尿路感染患者的病原菌分布和耐药性分析

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1016 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂治疗2型糖尿病过程中并发尿路感染患者的病原菌分布及其耐药性。方法回顾性分析2020-01至2023-12武警重庆总队医院门诊及住院使用SGLT-2抑制剂治疗2型糖尿病并发尿路感染患者共231例的临床资料,对其尿液样本、微生物培养和药敏试验方法进行分析。结果共分离病原菌231株,其中革兰氏阳性菌37株(16.02%),革兰氏阴性菌182株(78.79%),真菌12株(5.19%)。革兰氏阳性菌中粪肠球菌18株(48.65%,18/37),屎肠球菌9株(24.32%,9/37);多重耐药菌14株(37.84%,14/37),其中粪肠球菌7株和屎肠球菌7株。革兰氏阴性菌中大肠埃希菌156株(85.71%,156/182),肺炎克雷伯杆菌13株(7.14%,13/182);多重耐药菌84株(46.15%,84/182),其中大肠埃希菌81株和肺炎克雷伯杆菌3株为产ESBLs菌株。药敏试验分析:大肠杆菌对氨苄西林和环丙沙星的耐药率最高(分别为81.94%和79.35%),对碳青霉烯类、替加环素和呋喃妥因的敏感性较高。肺炎克雷伯菌对喹诺酮类药物的耐药率为76.92%,对碳青霉烯类、替加环素和头孢哌酮/舒巴坦则完全敏感。粪肠球菌和屎肠球菌均对多种抗生素表现出较高的耐药性,但对万古霉素、替考拉宁和利奈唑胺敏感性高。结论 SGLT-2抑制剂治疗2型糖尿病患者并发尿路感染的病原菌分布以大肠埃希菌等革兰氏阴性菌为主,部分革兰氏阳性菌、少量真菌。由于SGLT-2抑制剂的药理机制,多重耐药菌占比较高,临床需据药敏试验合理用药。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张春
	余丽
	崔龙
	杨威
	王晓宏

关键词 ： 2型糖尿病, 钠-葡萄糖协同转运蛋白2抑制剂, 尿路感染, 病原菌, 药敏试验

Abstract：Objective To investigate the distribution and drug resistance of pathogens associated with urinary tract infections (UTIs) in the treatment of type 2 diabetes with sodium-glucose cotransporter 2 (SGLT-2) inhibitors. Methods A retrospective analysis was conducted on 231 patients with type 2 diabetes who were treated with SGLT-2 inhibitors and developed UTIs from January 2020 to December 2023 in Chongqing Municipal Corps Hospital of Chinese People's Armed Police Force. The distribution of pathogens and the resistance of the main isolates were analyzed using routine urine analysis, urine microbial culture and antimicrobial susceptibility testing. Results A total of 231 strains of pathogens were isolated, of which 37 were Gram-positive bacteria (16.02%), 182 were Gram-negative bacteria (78.79%), and 12 were fungi (5.19%). Among the Gram-positive bacteria, 18 strains were Enterococcus faecium (48.65%, 18/37) and 9 strains were Enterococcus faecalis (24.32%, 9/37); 14 strains were multidrug-resistant bacteria (37.84%, 14/37), including 7 strains each of enterococcus faecium and enterococcus faecalis. Among the Gram-negative bacteria, there were 156 strains of Escherichia coli (85.71%, 156/182) and 13 strains of Klebsiella pneumoniae (7.14%, 13/182); 84 strains were multidrug-resistant (46.15%, 84/182), of which 81 strains of Escherichia coli and 3 strains of Klebsiella pneumoniae produced extended-spectrum beta-lactamases (ESBLs).Antimicrobial susceptibility test showed that Escherichia coli had the highest resistance rate to ampicillin and ciprofloxacin (81.94% and 79.35%, respectively), but was more sensitive to carbapenems, tigecycline, and nitrofurantoin. Klebsiella pneumoniae demonstrated a resistance rate of 76.92% to quinolone antibiotics, but was completely sensitive to carbapenems, tigecycline, and cefepime/sulbactam. Both Enterococcus faecium and Enterococcus faecalis exhibited high resistance to a variety of antibiotics, yet showed high sensitivity to vancomycin, teicoplanin, and linezolid. Conclusions The main pathogenic bacteria in the treatment of type 2 diabetes patients with urinary tract infection by SGLT-2 inhibitors are Gram-negative bacteria such as Escherichia coli, with some infections also involving Gram-positive bacteria and a small amount of fungi. Due to the pharmacological mechanism of SGLT-2 inhibitors, there is a higher proportion of multidrug-resistant bacteria, and it is clinically essential to use medication rationally based on antibiogram results.

Key words： type 2 diabetes inhibitor of sodium-glucose cotransporter 2 urinary tract infection pathogen antimicrobial susceptibility test

收稿日期: 2024-06-11

ZTFLH:

R587.1

基金资助:重庆市南岸区科卫联合医学科研项目(2023-04)

通讯作者: 王晓宏,E-mail:35061566@qq.com

作者简介: 张春,本科学历,副主任医师。

引用本文:

张春, 余丽, 崔龙, 杨威, 王晓宏. 钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病并发尿路感染患者的病原菌分布和耐药性分析[J]. 武警医学, 2024, 35(9): 754-757. ZHANG Chun, YU Li, CUI Long, WEI Wang, WANG Xiaohong. Analysis of pathogens and antimicrobial resistance of sodium-glucose cotransporter 2 inhibitors in treatment of urinary tract infection in patients with type 2 diabetes. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(9): 754-757.

链接本文:

https://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 https://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2024/V35/I9/754

[1]	中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.
[2]	熊哲学,李凝旭,唐明娟.钠-葡萄糖协同转运蛋白2抑制剂对足细胞自噬影响及其肾脏保护机制的研究进展[J].中国糖尿病杂志,2022,30(7):554-557.
[3]	纪立农,郭立新,郭晓蕙,等.钠-葡萄糖共转运蛋白2(SGLT2)抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志,2016,24(10):865-870.
[4]	Go A,Daisuke K,Kenji O, et al.Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections-a cross sectional analysis of a nationwide Japanese claims database[J].Endocr J,2023,70(11):1103-1107.
[5]	Keisuke T,Masahiko G.Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: an observational study[J].Fundam Clin Pharmacol,2022,36(6):1106-1114.
[6]	Despoina V,Thomas K,Eleni A, et al.Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.[J].Ann Intern Med,2013,159(4):262-274.
[7]	中华人民共和国卫生部. 医院感染诊断标准(试行)[J].中华医学杂志,2001,81(5):314-320.
[8]	2011版《中国泌尿外科疾病诊断治疗指南》出版发行[J].泌尿外科杂志(电子版),2011,3(3):54.
[9]	尚红,王毓三,申子瑜.全国临床检验操作规程[M].4版.北京:人民卫生出版社,2015:62-86.
[10]	Fone J H,John S.Analysis and presentation of cumulative antibiograms: a new consensus guideline from the clinical and laboratory standards institute[J].Clin Infect Dis,2007,44(6):867-873.
[11]	Giri B,Dey S,Das T, et al.Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity[J].Biomed Pharmacother,2018,107:306-328.
[12]	Fatma H,Makram K,Amal C, et al.1697. The burden of multidrug-resistant urinary tract infections[J].Open Forun Infect Dis,2020,7(Suppl 1):S831-S831.
[13]	薛笑楠,郑伟坤,官雯娟,等.2型糖尿病并发尿路感染病原学和耐药性及其危险因素[J/OL].中华医院感染学杂志,2024(5):703-706.
[14]	Louise S.Effect of high glucose on E coli[J].Nat Rev Urol,2023,20(1):7.
[15]	Eickhoff K M,Dekkers J C,Kramers J B, et al.Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors[J].J. Clin Med,2019,8(6):779-779.
[16]	Eleazar B C.Functional linkage between genes that regulate osmotic stress responses and multidrug resistance transporters: challenges and opportunities for antibiotic discovery[J]. Antimicrob Agents Chemother,2014,58(2):640-646.
[17]	Dantas T P,Gastalho C L,Luciene C, et al.Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule[J].JASN,2014,25(9):2028-2039.
[18]	S D I,Ella H,C G U.The basics of bacteriuria: strategies of microbes for persistence in urine[J].Front Cell Infect Microbiol,2016,8(6):14.
[19]	Hiroshige M,Yuka Y,Hiroyuki S, et al.High glucose-mediated overexpression of ICAM-1 in human vaginal epithelial cells increases adhesion of Candida albicans[J].J Obstet Gynaecol,2018,38(2):226-230.
[20]	Hu R,Xia C,Butfiloski E, et al.Effect of high glucose on cytokine production by human peripheral blood immune cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory process and host defense against infection[J].Clin Immunol,2018,195:139-148.